Acitrin-L Oral Solution 2.5 mg/5 ml

Acitrin-L Oral Solution, manufactured by ACI Limited, contains Levocetirizine Dihydrochloride 2.5 mg/5 ml as a non-sedating antihistamine. This oral solution effectively treats allergic rhinitis and chronic idiopathic urticaria, offering rapid and long-lasting relief with once-daily dosing.

Priced at ৳55.00 per unit, it is cost-effective for managing seasonal allergies. The solution is suitable for patients aged 6 months and above, with dosage adjustments for renal impairment. Store below 30°C in dry conditions, protected from light to maintain efficacy.

Clinical studies show Levocetirizine (generic information) binds H1-receptors twice as effectively as cetirizine. Common side effects include dry mouth and headache. Not recommended during lactation due to secretion in breast milk. No significant drug interactions reported.

For precise dosing:

• Adults: 5 mg (10 ml) daily
• Children 6-11 years: 2.5 mg (5 ml) daily
• Infants 6 months-5 years: 1.25 mg (2.5 ml) daily

As a therapeutic alternative to sedating antihistamines, Acitrin-L Oral Solution minimizes drowsiness while controlling allergy symptoms. Consult healthcare providers for renal impairment adjustments or pregnancy-related use despite its Category B classification.

Adults: 5 mg (10 ml) once daily. Children 6-11 years: 2.5 mg (5 ml), 6 months-5 years: 1.25 mg (2.5 ml). Renal impairment requires dose adjustment: CrCl 30-50 mL/min – 2.5 mg every 48 hours. Administer oral solution with/without food.

Generally, levocetirizine is well tolerated. However, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely.

Pregnancy Category B: Use only if clearly needed. Avoid during lactation due to excretion in breast milk.

Precaution needed in epilepsy/seizure disorders. Renal function monitoring required. May impair driving ability.

Geriatric patients require renal function assessment. No dose adjustment in hepatic impairment. Pediatric dosing must follow age-specific guidelines.

No clinically relevant adverse events have been reported in case of overdose. However in the event of overdosage, symptomatic and supportive treatment is recommended.